Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2021-10-28 Report Publication Anno…
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3329 characters) released via RNS (RNS Number : 6267Q) from Genedrive plc. The core content is the 'Notice of Results,' stating that the company 'will release its financial results for the year ended 30 June 2021 on Tuesday 9 November 2021.' It also mentions an accompanying presentation. According to Rule 2 ('MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than containing the full report itself, should be classified as a Report Publication Announcement (RPA). This is a clear announcement about the timing of a future report release.
2021-10-28 English
Director's shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a notification regarding a 'Director's Shareholding' change due to an administrative error. The structure includes a detailed table titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This specific type of filing, detailing personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the content is highly specific to insider trading disclosure.
2021-10-11 English
Result of General Meeting
AGM Information Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces the 'Result of General Meeting' where resolutions were passed. While this relates to shareholder voting (DVA), the format is a standard regulatory news service announcement disseminated via RNS. Given the short length (under 5,000 characters) and the nature of it being a brief announcement of an event result rather than the full minutes or proxy materials, it fits best as a general Regulatory Filing (RNS), which serves as the fallback for official news releases from the LSE's primary information provider that don't fit a more specific category like DIV or DVA (which usually relates to the actual voting results document itself, not the announcement of the result). Since RNS is the source and the document is a brief update, RNS is the most appropriate classification.
2021-09-30 English
Result of Open Offer
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is clearly identified as an RNS announcement (RNS Number : 2958N) from the London Stock Exchange's news service. The content announces the 'Result of Open Offer' which is a capital raising/financing activity, detailing proceeds raised (£1.1 million from the Open Offer, £7.1 million total) and the subsequent application for admission of new shares. Crucially, it also contains a detailed section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' detailing the purchase of shares by Directors (David Budd, Matthew Fowler, etc.) as part of the Open Offer. While it discusses capital raising (CAP) and insider transactions (DIRS), the primary nature of the filing, as indicated by the RNS header and the comprehensive disclosure of director participation in the transaction, strongly suggests it is a regulatory disclosure related to insider dealings following a capital event. However, the core event being reported is the result of a capital raise (Open Offer) and the associated director participation. Since the document details the results of a financing activity and explicitly lists director participation in that activity, it touches upon CAP and DIRS. Given the structure, which is a formal regulatory announcement (RNS) reporting on the outcome of a capital raise and the resulting insider transactions, the most fitting primary category is related to capital changes or regulatory disclosure. Since it details the purchase of new shares by directors as part of the Open Offer, it is a specific disclosure of insider activity following a capital event. The presence of the detailed director transaction table strongly points towards Director's Dealing (DIRS). If it were purely CAP, it would focus only on the capital structure change. If it were purely DIRS, it would focus only on insider trades without the context of the Open Offer results. Since the RNS format is used for general regulatory announcements, and this specific announcement details director participation in a capital raise, DIRS is a strong candidate, but the overall context is a financing result. Given the explicit listing of director purchases (80,000 shares by CEO, etc.), DIRS is highly relevant. However, the document is fundamentally an announcement of the result of a capital raising exercise ('Result of Open Offer'). The director participation is a required disclosure *within* that context. Since the document is a full regulatory announcement published via RNS, and it details a significant capital raising event, 'CAP' (Capital/Financing Update) is appropriate, but 'RNS' (General Regulatory Filings) is the most accurate umbrella if the specific nature isn't perfectly captured. Let's re-evaluate based on the definitions. It is not a standard 10-K, AR, ER, or IR. It is a specific announcement of a financing result. The director participation section is a mandatory disclosure under MAR/DTR rules following such an event. Because the document is a full, detailed regulatory announcement (RNS format) reporting on the outcome of a capital raise and associated director dealings, and RNS is the fallback for specific regulatory announcements, RNS is a safe classification. However, the content is highly specific to capital raising and insider transactions. Given the explicit listing of director purchases (which falls under DIRS), and the context of the capital raise (CAP), I will prioritize the most specific event being disclosed: the capital raise result, which is a financing update. The RNS header confirms it is a regulatory filing, but the content is about capital. I will select RNS as the most accurate catch-all for this specific LSE regulatory news item that combines financing results and director dealings disclosure, as it is not a pure CAP or pure DIRS document, but a formal RNS announcement detailing both.
2021-09-29 English
New Genedrive System receives CE-IVD marking
Environmental & Social Information Classification · 1% confidence The document begins with 'RNS Number : 2908N' and is dated September 29, 2021. It announces a significant operational update: 'New Genedrive® System receives CE-IVD marking' and discusses commercial launch plans. This is a typical announcement made via the Regulatory News Service (RNS) system of the London Stock Exchange. Since it is a general, material, non-financial announcement that doesn't fit into specific categories like ER, 10-K, or DIV, the most appropriate classification is the general regulatory announcement category, RNS.
2021-09-29 English
Publication of Circular and Notice of GM
AGM Information Classification · 1% confidence The document is an RNS announcement dated September 14, 2021, titled "Publication of Circular and Notice of General Meeting." It details the terms of an Open Offer following a Placing, sets out a timetable for the General Meeting (scheduled for September 30, 2021), and mentions that the Circular containing the notice will be posted to shareholders. Since the document's primary purpose is to announce the publication of a Circular and the convening of a General Meeting, it relates directly to shareholder voting and meeting procedures. The most specific category for materials related to general meetings and associated documentation (like a Notice of Meeting or Circular) is AGM-R (AGM Information) or potentially PSI (Proxy Solicitation & Information Statement). However, the document explicitly announces the publication of the Circular and the Notice of General Meeting, which are core components of the AGM process. Given the context of announcing the meeting and the associated documentation, AGM-R is the most appropriate fit, although RPA (Report Publication Announcement) is also plausible as it announces the publication of the Circular. Since the content focuses heavily on the meeting mechanics (date, time, Open Offer terms tied to the meeting), AGM-R is prioritized over the general RPA.
2021-09-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.